Correlates of protective immunity to Mycobacterium tuberculosis in humans

J. J. Ellner, C. S. Hirsch, C. C. Whalen

Research output: Contribution to journalArticle

Abstract

Correlates of protective immunity to Mycobacterium tuberculosis in humans are desirable for identifying protective antigens, demonstrating the immunogenicity of a vaccine candidate and its potential efficacy, and permitting optimization of the dose, vehicle, adjuvant, and schedule of immunization. Potential correlates can be proposed on the basis of animal models and ex vivo/in vitro studies in humans. Most critical is their validation; ultimate validation will require correlation with protection in a phase III efficacy trial of an effective vaccine. Other approaches, however, can allow selection of the most promising correlates for inclusion in phase I and II and, ultimately, phase III vaccine trials. Current data from experimental models and studies of patients with pulmonary tuberculosis and their household contacts indicate that Mycobacterium tuberculosis-stimulated whole-blood production of interferon-γ, although imperfect, is the best available correlate. Nonetheless, further refinement of this assay and additional studies of more complex assays that model M. tuberculosis killing and cytotoxic T lymphocyte activity are warranted. During planning of a vaccine trial, the best available correlates of immunity can be selected for inclusion.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume30
Issue numberSUPPL. 3
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Mycobacterium tuberculosis
Immunity
Vaccines
Immunization Schedule
Cytotoxic T-Lymphocytes
Pulmonary Tuberculosis
Interferons
Theoretical Models
Animal Models
Antigens

ASJC Scopus subject areas

  • Immunology

Cite this

Correlates of protective immunity to Mycobacterium tuberculosis in humans. / Ellner, J. J.; Hirsch, C. S.; Whalen, C. C.

In: Clinical Infectious Diseases, Vol. 30, No. SUPPL. 3, 2000.

Research output: Contribution to journalArticle

Ellner, J. J. ; Hirsch, C. S. ; Whalen, C. C. / Correlates of protective immunity to Mycobacterium tuberculosis in humans. In: Clinical Infectious Diseases. 2000 ; Vol. 30, No. SUPPL. 3.
@article{daf07b2c04d44e14a60428045c1eba98,
title = "Correlates of protective immunity to Mycobacterium tuberculosis in humans",
abstract = "Correlates of protective immunity to Mycobacterium tuberculosis in humans are desirable for identifying protective antigens, demonstrating the immunogenicity of a vaccine candidate and its potential efficacy, and permitting optimization of the dose, vehicle, adjuvant, and schedule of immunization. Potential correlates can be proposed on the basis of animal models and ex vivo/in vitro studies in humans. Most critical is their validation; ultimate validation will require correlation with protection in a phase III efficacy trial of an effective vaccine. Other approaches, however, can allow selection of the most promising correlates for inclusion in phase I and II and, ultimately, phase III vaccine trials. Current data from experimental models and studies of patients with pulmonary tuberculosis and their household contacts indicate that Mycobacterium tuberculosis-stimulated whole-blood production of interferon-γ, although imperfect, is the best available correlate. Nonetheless, further refinement of this assay and additional studies of more complex assays that model M. tuberculosis killing and cytotoxic T lymphocyte activity are warranted. During planning of a vaccine trial, the best available correlates of immunity can be selected for inclusion.",
author = "Ellner, {J. J.} and Hirsch, {C. S.} and Whalen, {C. C.}",
year = "2000",
doi = "10.1086/313874",
language = "English (US)",
volume = "30",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Correlates of protective immunity to Mycobacterium tuberculosis in humans

AU - Ellner, J. J.

AU - Hirsch, C. S.

AU - Whalen, C. C.

PY - 2000

Y1 - 2000

N2 - Correlates of protective immunity to Mycobacterium tuberculosis in humans are desirable for identifying protective antigens, demonstrating the immunogenicity of a vaccine candidate and its potential efficacy, and permitting optimization of the dose, vehicle, adjuvant, and schedule of immunization. Potential correlates can be proposed on the basis of animal models and ex vivo/in vitro studies in humans. Most critical is their validation; ultimate validation will require correlation with protection in a phase III efficacy trial of an effective vaccine. Other approaches, however, can allow selection of the most promising correlates for inclusion in phase I and II and, ultimately, phase III vaccine trials. Current data from experimental models and studies of patients with pulmonary tuberculosis and their household contacts indicate that Mycobacterium tuberculosis-stimulated whole-blood production of interferon-γ, although imperfect, is the best available correlate. Nonetheless, further refinement of this assay and additional studies of more complex assays that model M. tuberculosis killing and cytotoxic T lymphocyte activity are warranted. During planning of a vaccine trial, the best available correlates of immunity can be selected for inclusion.

AB - Correlates of protective immunity to Mycobacterium tuberculosis in humans are desirable for identifying protective antigens, demonstrating the immunogenicity of a vaccine candidate and its potential efficacy, and permitting optimization of the dose, vehicle, adjuvant, and schedule of immunization. Potential correlates can be proposed on the basis of animal models and ex vivo/in vitro studies in humans. Most critical is their validation; ultimate validation will require correlation with protection in a phase III efficacy trial of an effective vaccine. Other approaches, however, can allow selection of the most promising correlates for inclusion in phase I and II and, ultimately, phase III vaccine trials. Current data from experimental models and studies of patients with pulmonary tuberculosis and their household contacts indicate that Mycobacterium tuberculosis-stimulated whole-blood production of interferon-γ, although imperfect, is the best available correlate. Nonetheless, further refinement of this assay and additional studies of more complex assays that model M. tuberculosis killing and cytotoxic T lymphocyte activity are warranted. During planning of a vaccine trial, the best available correlates of immunity can be selected for inclusion.

UR - http://www.scopus.com/inward/record.url?scp=0034463153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034463153&partnerID=8YFLogxK

U2 - 10.1086/313874

DO - 10.1086/313874

M3 - Article

VL - 30

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 3

ER -